TPST • NASDAQ
Tempest Therapeutics, Inc.
$2.05
Stock Details
| Market Cap | 9,103,841 |
|---|---|
| Day Change | 0.47 (29.75%) |
| Volume | 1,689,909 |
| Avg Volume | 147,880 |
| Price Range | 1.5-12.23 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Financial Overview
| 52 Week High | 12.23 |
|---|---|
| 52 Week High Date | 2025-10-15 |
| 52 Week Low | 1.5 |
| 52 Week Low Date | 2026-03-31 |
| 10D Avg Trading Vol | 0.30952 |
| YTD Price Return Daily | -28.5714 |
| MTD Price Return Daily | 25 |
Cash Flow
| TTM/Share | -2.1956 |
|---|---|
| Annual/Share | -9.8929 |
| Quarterly/Share | -7.5218 |
Price-to-Earnings
| Annual Ratio | 2.2134 |
|---|---|
| Quarterly Ratio | 2.299 |
| TTM |
Revenue
| 3Y Growth | |
|---|---|
| 5Y Growth | |
| Annual/Share | |
| TTM/Share | 1.875 |
| 5Y Share Growth |
Earnings Per Share
| Annual | -19.4963 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 4.6337 |
|---|---|
| Annual Ratio | 1.9042 |
| TTM | 7.1927 |